Ads
related to: demyelinating polyneuropathy
Search results
Olympic Swimmer Michael Klim Reveals CIDP Diagnosis: 'My Health Began to 'Deteriorate Drastically'
People via Yahoo News· 2 years agoHanna Lassen/Getty Australian Olympic swimmer Michael Klim is opening up about his recent health...
Everything You Need to Know About POEMS Syndrome
Verywell Health via Yahoo News· 10 months agoA Rare Multisystem Disease Mladen Zivkovic / Getty Images Medically reviewed by Doru Paul, MD Polyneuropathy, organomegaly, endocrinopathy, monoclonal...
North Myrtle Beach man to be featured in national awareness campaign for rare disorder
WBTW Myrtle Beach via Yahoo News· 1 month agoHORRY COUNTY, S.C. (WBTW) — A North Myrtle Beach man with a rare autoimmune disorder will be...
'A hospital within a hospital': St. Vincent Children’s Hospital expands services
Green Bay Press-Gazette via Yahoo News· 1 year agoGREEN BAY - It was a lot of firsts for 14-year-old Emma who came from Peshtigo to go to her first...
Guillain-Barré Syndrome (GBS): Everything You Need to Know
Verywell Health via Yahoo News· 6 months agoAlso Known as Acute Inflammatory Demyelinating Polyneuropathy (AIDP)Medically reviewed by David...
The Multibillion-Dollar Opportunity That Sent Argenx Flying 28% Into A Breakout
Investor's Business Daily· 10 months agoAn Argenx drug beat Wall Street's expectations in a study of patients with a progressive nerve...
Why Shares of Argenx Jumped This Week
Motley Fool· 10 months agoShares of Argenx SE (NASDAQ: ARGX) were up more than 44% for the week as of 12:15 p.m. ET on Friday, according to data provided by S&P Global Market...
Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering
Investor's Business Daily· 8 months agoImmunovant stock dipped Wednesday after the drugmaker announced a $300 million offering on the heels...
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
Motley Fool via Yahoo Finance· 4 months agoBiotech could be on the verge of a major comeback in 2024. The main reason for this expected...
Why Shares of Roivant Sciences Were Down Tuesday
Motley Fool· 1 year agoWhat happened Shares of Roivant Sciences (NASDAQ: ROIV) were down 13.26% in mid-morning trading on Tuesday. The biotech company, which specializes in...
